secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059093
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology Q1 net loss narrows to $3.3M; PYX-201 data on track for fall 2024
--------------------------------------------------------------------------------

- Revenue of $16.1M from Novartis royalty settlement; net loss $3.3M ($0.06/sh) vs $19.2M ($0.54/sh) YoY.
- Cash & investments $158.5M; runway into 2H 2026; raised ~$60.8M via ATM, private placement, and Novartis deal.
- PYX-201 Phase 1: 42 patients dosed; 16 more planned; results including efficacy expected fall 2024.
- PYX-106 Phase 1: 24 subjects dosed; preliminary data anticipated in 2H 2024.
- Appointed Stephen Worsley as Senior Vice President, Chief Business Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017024059093/0000950170-24-059093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017024059093/pyxs-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer